Wells Fargo & Company Rezolute, Inc. Transaction History

Wells Fargo & Company

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$0.95 - $2.55 $20 - $56	22 Added 9.36%	257 $0
Q4 2023 Feb 09, 2024	BUY	$0.74 - $1.24 $8 - $14	12 Added 5.38%	235 $0
Q3 2023 Nov 13, 2023	SELL	$1.32 - $2.1 $6 - $10	-5 Reduced 2.19%	223 $0
Q2 2023 Aug 15, 2023	BUY	$1.75 - $2.33 $15 - $20	9 Added 4.11%	228 $0
Q1 2023 May 12, 2023	BUY	$1.79 - $2.87 $5 - $8	3 Added 1.39%	219 $0
Q4 2022 Feb 13, 2023	BUY	$1.38 - $2.84 $33 - $68	24 Added 12.5%	216 $0
Q3 2022 Nov 14, 2022	SELL	$2.19 - $3.49 $13 - $20	-6 Reduced 3.03%	192 $1,000
Q2 2022 Aug 12, 2022	BUY	$2.6 - $3.85 $327 - $485	126 Added 175.0%	198 $1,000
Q1 2022 May 16, 2022	BUY	$2.27 - $5.1 $2 - $5	1 Added 1.41%	72 $0
Q4 2021 Feb 14, 2022	BUY	$4.21 - $7.61 $181 - $327	43 Added 153.57%	71 $0
Q3 2021 Nov 15, 2021	BUY	$7.45 - $13.66 $208 - $382	28 New	28 $0

38.5M

1.6K

24.6K

Ticker RZLT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,827,600
Market Cap $172M
Description
Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultr...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.